Abstract
Background: Arsenic trioxide (As2O3) has been demonstrated to suppress tumorigenesis in human glioma. However, the exact molecular mechanisms by which As2O3 exerts its tumor suppressor functions are elusive. Therefore, it is warranted to explore the underlying mechanism of As2O3–mediated anti-tumor activity in glioma.
Methods: To achieve our goal, we used multiple approaches including MTT assay, apoptosis, Real-time RT-PCR, Western blotting, invasion assay, and gene transfection.
Results: We observed that A22O3 inhibited cell growth and induced apoptosis as well as suppressed migration and invasion in human glioma cells. Moreover, we found that As2O3 down-regulated miR-125b expression and subsequently up-regulated its target gene Bak1 expression. Furthermore, we identified that As2O3 exerts its anti-tumor activity partly through regulation of miR-125b.
Conclusions: Our present study suggests that As2O3 could be a potential therapeutic agent for treatment of human glioma.
Current Pharmaceutical Design
Title:Arsenic Trioxide Targets miR-125b in Glioma Cells
Volume: 20 Issue: 33
Author(s): Sulian Chen, Lihua Zhu, Jing Huang, Ying Cai, Xiaohui Lu, Qingling Yang, Qiong Wu, Changjie Chen and Zhiwei Wang
Affiliation:
Keywords: As2O3, glioma, invasion, miR-125b, Bak1.
Abstract: Background: Arsenic trioxide (As2O3) has been demonstrated to suppress tumorigenesis in human glioma. However, the exact molecular mechanisms by which As2O3 exerts its tumor suppressor functions are elusive. Therefore, it is warranted to explore the underlying mechanism of As2O3–mediated anti-tumor activity in glioma.
Methods: To achieve our goal, we used multiple approaches including MTT assay, apoptosis, Real-time RT-PCR, Western blotting, invasion assay, and gene transfection.
Results: We observed that A22O3 inhibited cell growth and induced apoptosis as well as suppressed migration and invasion in human glioma cells. Moreover, we found that As2O3 down-regulated miR-125b expression and subsequently up-regulated its target gene Bak1 expression. Furthermore, we identified that As2O3 exerts its anti-tumor activity partly through regulation of miR-125b.
Conclusions: Our present study suggests that As2O3 could be a potential therapeutic agent for treatment of human glioma.
Export Options
About this article
Cite this article as:
Chen Sulian, Zhu Lihua, Huang Jing, Cai Ying, Lu Xiaohui, Yang Qingling, Wu Qiong, Chen Changjie and Wang Zhiwei, Arsenic Trioxide Targets miR-125b in Glioma Cells, Current Pharmaceutical Design 2014; 20 (33) . https://dx.doi.org/10.2174/1381612820666140128204132
DOI https://dx.doi.org/10.2174/1381612820666140128204132 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Copper Compounds in Anticancer Strategies
Current Medicinal Chemistry Sesamol Induces Apoptosis by Altering Expression of Bcl-2 and Bax Proteins and Modifies Skin Tumor Development in Balb/c Mice
Anti-Cancer Agents in Medicinal Chemistry Development of 96-microwell Plate Assay with Fluorescence Reader and HPLC Method with Fluorescence Detection for High-throughput Analysis of Linifanib in its Bulk and Dosage Forms
Current Pharmaceutical Analysis The Extracellular Matrix Regulates Cancer Progression and Therapy Response: Implications for Prognosis and Treatment
Current Pharmaceutical Design Interrelation of Major Depression and Antidepressant Transcriptomics
Current Psychopharmacology Immunotherapy with Tumor Vaccines for the Treatment of Malignant Gliomas
Current Drug Discovery Technologies Epigenetic Regulation of Epithelial-Mesenchymal Transition by Hypoxia in Cancer: Targets and Therapy
Current Pharmaceutical Design Prospects for Anti-Neoplastic Therapies Based on Telomere Biology
Current Cancer Drug Targets Possible Considerations for the Management of Turcot’s Syndrome?
Current Cancer Therapy Reviews Automated Brain Tumor Segmentation from MRI Images using Morphometric Algorithms
Current Signal Transduction Therapy Hologram QSAR Studies of N,N-Dialkyl-2-phenylindol-3-ylglyoxylamides Derivatives as Selective Peripheral Benzodiazepine Receptor Ligands
Letters in Drug Design & Discovery Epigallocatechin-3-gallate Increases RXRγ-mediated Pro-apoptotic and Anti-invasive Effects in Gastrointestinal Cancer Cell Lines
Current Cancer Drug Targets Targeting the BRCA1/2 Tumor Suppressors
Current Drug Targets Protein/ Hormone Based Nanoparticles as Carriers for Drugs Targeting Protein-Protein Interactions
Current Topics in Medicinal Chemistry A QSAR Study on Novel Series of Carbonic Anhydrase Inhibitors hCA IX—Tumor-Associated (Hypoxia)
Medicinal Chemistry Mitochondrial Superoxide Dismutase - Signals of Distinction
Anti-Cancer Agents in Medicinal Chemistry Cancer-associated Autoantibodies as Biomarkers for Early Detection and Prognosis is Cancer: An Update
Current Cancer Therapy Reviews Mitochondria in Cancer Stem Cells: A Target for Therapy
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery (Discontinued) Base Excision Repair: Contribution to Tumorigenesis and Target in Anticancer Treatment Paradigms
Current Medicinal Chemistry Therapeutic Peptide Mimetics Looking for a Turn to Block Aberrant Players of Malignancy
Current Cancer Therapy Reviews